Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveDrug-Initiated Synthesis of Polymer Prodrugs: Combining Simplicity and Efficacy in Drug DeliverySystemic therapies for pancreatic cancer--the role of pharmacogeneticsChemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyH-gemcitabine: a new gemcitabine prodrug for treating cancerCombination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cellsGene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?PharmGKB summary: gemcitabine pathwayDeoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Antimetabolite Treatment for Pancreatic Cancer.Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Preparation and evaluation of polymeric microparticulates for improving cellular uptake of gemcitabine.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatmentPreclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure.Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse HepatocarcinomaCheckpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.Dr Jekyll and Mr Hyde: a strange case of 5-ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidine.5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study.Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine.Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma.Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.Pancreatic Cancer Chemoresistance to Gemcitabine.Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
P2860
Q26752368-926F81B3-D195-4319-B713-0168CFE14B09Q26752989-72EC9F4D-A56C-4CA2-9F2C-7E91B85817A5Q27021716-886E1515-511E-4FF5-A31D-1FF538798393Q27693179-4DCACDEE-7A9E-47D1-AA51-91C259558D33Q28471821-C0EF99C3-9B70-43B1-AF69-662F845E01C7Q28484288-9C5B7AE2-BAA2-41F0-B336-AAE13B9DB117Q33572635-C906607C-E9F1-4A0B-B525-98FA71C205FAQ33670961-7788862D-4C21-494B-AE9B-7395B70C4694Q34177223-2380C776-F823-4F3C-BDED-DC37B35F7776Q34205171-F78EE00A-5904-4DD5-A723-0CD8232E9BF4Q34435450-FDD0CEED-3163-43EA-BB44-9CCEDC33A883Q34438371-959BAEE3-587A-4B1C-95C2-B7DC31CD5828Q35675274-94CBE51F-5D7C-4949-BF30-BFE5220EEC11Q35826334-CE866768-434C-4F3C-A0E9-69E901DF9A46Q35909171-1E136855-74C1-41B6-98D4-929C37BB4846Q35979136-45DF8BE9-6FBA-49B0-AE14-BB95EA3077F0Q36094941-24197C78-5283-443B-B24F-0A50B3FF189EQ36610851-69F92C1D-406C-4D3A-9C77-5A5E7294E54BQ36924856-73E98995-D5D3-480E-B3B8-E45CE8308FC1Q36975151-7D8AD198-E205-4F8F-881C-A3BA3B39B9E4Q37206486-353D2C2A-FC94-493F-83BB-87B560883CECQ37327880-53633F27-4F69-4B57-94E7-B6C5D7047957Q37413849-F73A8D3A-0595-4AD0-AB92-A4DECBED7C04Q37528662-8EA9073D-E9D7-493E-8FD6-DC445BDCD628Q37555069-81AE5D7F-C010-4F23-B097-A3D574709D86Q37595491-5186EBB0-3A66-40CA-94EE-B3180634ECFEQ37994505-8A11A70E-F41F-4BF7-A7C7-8DB02951098BQ38631350-7479D8ED-4186-4D7A-9A66-9573D47E0EABQ38805955-0F2CB917-A2A4-45AC-92FC-50930EA32C10Q39080441-5812B870-A0F0-48B7-A7BE-565294F84079Q39222400-011F33A4-05E8-4F00-9464-B4AFE8A7F68BQ39784049-A52E7AE2-1EB9-4396-9179-CFBF4430CDDBQ41044200-6CAC7060-A135-4A39-B839-7B4737268A38Q41480926-9EFA9AF0-ED80-4E4E-B8AA-B3284456A4F2Q41931773-CA2DA903-87BB-46E4-B385-A092781A20FDQ45062589-C73C700F-7A17-4CA8-B3C5-5306F2010E45Q47135556-A83ADFBB-603A-483D-A297-20F547004EE9Q48099410-60DA32D4-B70D-4536-ABE1-348FDABF36B0Q48112706-EB5A67A6-A30B-4A11-B93B-89C98ABF45D4Q49929146-9EA88495-8546-4FF7-BBC8-DA298F439354
P2860
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Cellular elimination of 2',2'- ...... echanism of self-potentiation.
@en
type
label
Cellular elimination of 2',2'- ...... echanism of self-potentiation.
@en
prefLabel
Cellular elimination of 2',2'- ...... echanism of self-potentiation.
@en
P2093
P1433
P1476
Cellular elimination of 2',2'- ...... echanism of self-potentiation.
@en
P2093
G B Grindey
L W Hertel
V Heinemann
W Plunkett
P304
P407
P577
1992-02-01T00:00:00Z